MMC, VICC & TSU: Partners in Eliminating Cancer Disparities (1 of 3)

MMC、VICC

基本信息

  • 批准号:
    9356457
  • 负责人:
  • 金额:
    $ 141.43万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-09-26 至 2021-08-31
  • 项目状态:
    已结题

项目摘要

SUMMARY Particular emphasis is devoted in the US to identify the determinants of, and eventually remedies, for the disproportionate share of the cancer burden borne by underrepresented minorities. Incidence rates for many forms of cancer are higher among blacks than whites. The disparity is compounded by lower rates of relative survival for almost all cancers, so that age-adjusted mortality rates are substantially higher among African Americans than whites for about two-thirds of all types of cancers. Our Cancer Partnership provides an exceptional environment to focus the efforts of diverse investigators working across many disciplines to address health disparities in NCI designated cancer centers and to develop research infrastructure, capacity and effectiveness of minority-serving institutions. Collectively, these efforts offer the best opportunity to overcome cancer disparities and optimize research resources and infrastructure. Our Partnership has matured and developed strong, successful collaborative interactions based on excellence, true reciprocity and mutual benefit to achieve this goal. Moreover, this Partnership is geographically placed in a region with the highest cancer incidence in the US, pointing to the enormous potential for improved outcomes through the proposed work. We are dedicated to enhancing the strengths and eliminating the weaknesses of our three institutions as we move toward our shared goal of eliminating cancer disparities. The overall objectives of this competing renewal application are to: (1) increase and stabilize the competitive cancer research capability of Meharry Medical College (MMC) and Tennessee State University (TSU); (2) create stable, long-term collaborative relationships between MMC, TSU and the Vanderbilt Ingram Cancer Center (VICC) in cancer research, research education, career development and cancer outreach; (3) expand access to clinical trials for minority populations served by Nashville General Hospital (NGH)/MMC, and (4) improve the effectiveness of VICC research, career development, education and outreach activities specifically designed to benefit minority populations served by VICC. All activities will be monitored by an Internal Advisory Committee and the Program Steering Committee with representation from the NCI. A sustained and comprehensive Cancer Partnership is of immense benefit to the three participating institutions as well as the mid-South region of the US. The common mission statement for our Cancer Partnership is to conduct rigorous basic, translational and clinical research directed towards the reduction of disparities in the incidence and treatment of cancer through a multidisciplinary collaborative approach to research, education and community engagement. As a triad we will amplify cancer research capabilities in the greater Nashville academic and healthcare community, improve and document outcomes in the diagnosis and treatment of cancer in minority and underserved communities, minimize or eliminate measurable disparities in the incidence of cancer among minority populations, and fortify collaborations among the three partner organizations.
概括 美国特别重视确定导致这一问题的决定因素以及最终的补救措施。 代表性不足的少数群体承担了不成比例的癌症负担。许多人的发病率 黑人患癌症的比例高于白人。相对比率较低,加剧了这种差距。 几乎所有癌症的存活率都很高,因此非洲人的年龄调整死亡率要高得多 美国人比白人患约三分之二的所有类型的癌症。我们的癌症合作伙伴关系提供了 特殊的环境可以集中跨多个学科的不同研究人员的努力 解决 NCI 指定癌症中心的健康差异,并发展研究基础设施和能力 和少数族裔服务机构的有效性。总的来说,这些努力提供了最好的机会 克服癌症差异并优化研究资源和基础设施。我们的合作伙伴关系已经成熟 并在卓越、真正互惠和相互的基础上发展了强有力、成功的协作互动 有利于实现这一目标。此外,该伙伴关系在地理位置上位于最高的地区 美国癌症发病率,表明通过拟议的改善结果的巨大潜力 工作。我们致力于增强我们三个机构的优势并消除其弱点: 我们朝着消除癌症差异的共同目标迈进。本次竞赛的总体目标 续展申请的目的是:(1)增加和稳定Meharry的癌症研究竞争能力 医学院 (MMC) 和田纳西州立大学 (TSU); (2)建立稳定、长期的协作 MMC、TSU 和范德比尔特英格拉姆癌症中心 (VICC) 在癌症研究方面的关系, 研究教育、职业发展和癌症外展; (3) 扩大少数族裔参与临床试验的机会 纳什维尔综合医院 (NGH)/MMC 服务的人群,以及 (4) 提高 VICC 的有效性 专门为少数群体造福的研究、职业发展、教育和外展活动 VICC 服务的人群。所有活动将由内部咨询委员会和 项目指导委员会由 NCI 代表组成。持续且全面的癌症 伙伴关系对于三个参与机构以及中南地区都具有巨大的好处。 我们。我们癌症合作伙伴关系的共同使命宣言是进行严格的基础、转化和 旨在通过以下方式减少癌症发病率和治疗差异的临床研究 研究、教育和社区参与的多学科协作方法。作为黑社会的我们 将增强大纳什维尔学术和医疗保健社区的癌症研究能力,提高 并记录少数群体和服务欠缺社区的癌症诊断和治疗结果, 最大限度地减少或消除少数群体中癌症发病率的可测量差异,并加强 三个伙伴组织之间的合作。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Samuel Evans Adunyah其他文献

Samuel Evans Adunyah的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Samuel Evans Adunyah', 18)}}的其他基金

Admin Core
管理核心
  • 批准号:
    10889326
  • 财政年份:
    2023
  • 资助金额:
    $ 141.43万
  • 项目类别:
MMC, VICC & TSU: Partners in Eliminating Cancer Disparities ( 1 of 3)
MMC、VICC
  • 批准号:
    8534727
  • 财政年份:
    2011
  • 资助金额:
    $ 141.43万
  • 项目类别:
MMC, VICC & TSU: Partners in Eliminating Cancer Disparities (1 of 3)
MMC、VICC
  • 批准号:
    10012757
  • 财政年份:
    2011
  • 资助金额:
    $ 141.43万
  • 项目类别:
MMC, VICC & TSU: Partners in Eliminating Cancer Disparities (1 of 3)
MMC、VICC
  • 批准号:
    9211638
  • 财政年份:
    2011
  • 资助金额:
    $ 141.43万
  • 项目类别:
1/3) MMC, VICC, and TSU: Partners in Eliminating Cancer Disparities
1/3) MMC、VICC 和 TSU:消除癌症差异的合作伙伴
  • 批准号:
    10493417
  • 财政年份:
    2011
  • 资助金额:
    $ 141.43万
  • 项目类别:
Education and Training Core
教育培训核心
  • 批准号:
    10493432
  • 财政年份:
    2011
  • 资助金额:
    $ 141.43万
  • 项目类别:
Education and Training Core
教育培训核心
  • 批准号:
    10327937
  • 财政年份:
    2011
  • 资助金额:
    $ 141.43万
  • 项目类别:
Administration Core
行政核心
  • 批准号:
    8261507
  • 财政年份:
    2011
  • 资助金额:
    $ 141.43万
  • 项目类别:
MMC, VICC & TSU: Partners in Eliminating Cancer Disparities (1 of 3)
MMC、VICC
  • 批准号:
    9765041
  • 财政年份:
    2011
  • 资助金额:
    $ 141.43万
  • 项目类别:
1/3) MMC, VICC, and TSU: Partners in Eliminating Cancer Disparities
1/3) MMC、VICC 和 TSU:消除癌症差异的合作伙伴
  • 批准号:
    10705089
  • 财政年份:
    2011
  • 资助金额:
    $ 141.43万
  • 项目类别:

相似海外基金

University of Louisville Biomedical Integrative Opportunity for Mentored Experience Development -PREP (UL-BIOMED-PREP)
路易斯维尔大学生物医学综合指导经验开发机会 -PREP (UL-BIOMED-PREP)
  • 批准号:
    10557638
  • 财政年份:
    2023
  • 资助金额:
    $ 141.43万
  • 项目类别:
2/2 Collaborative Union for Cancer Research, Education, and Disparities (CURED)
2/2 癌症研究、教育和差异合作联盟 (CURED)
  • 批准号:
    10762045
  • 财政年份:
    2023
  • 资助金额:
    $ 141.43万
  • 项目类别:
Mayo Advancing Research Equity in ADRD Study in Jacksonville(MAREAS-Jax)
梅奥在杰克逊维尔推进 ADRD 研究中的研究公平性 (MAREAS-Jax)
  • 批准号:
    10729787
  • 财政年份:
    2023
  • 资助金额:
    $ 141.43万
  • 项目类别:
Investigating mitochondrial dysfunction in high-risk prostate cancer
研究高危前列腺癌中的线粒体功能障碍
  • 批准号:
    10570345
  • 财政年份:
    2023
  • 资助金额:
    $ 141.43万
  • 项目类别:
Howard University Summer Research Education Experience Program in Oral Health
霍华德大学口腔健康暑期研究教育体验项目
  • 批准号:
    10594263
  • 财政年份:
    2023
  • 资助金额:
    $ 141.43万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了